In:
Journal of Crohn's and Colitis, Oxford University Press (OUP), Vol. 18, No. 4 ( 2024-04-23), p. 540-547
Abstract:
We explored the potential for differential efficacy of vedolizumab between early and late ulcerative colitis [UC] with evaluation of clinical, endoscopic, and histological endpoints. Methods This was a multicentre, multinational, open-label study in patients with moderately-to-severely active UC, defining early UC by a disease duration & lt;4 years and bio-naïve and late UC by a disease duration & gt; 4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks [300 mg Weeks 0, 2, 6, every 8 weeks thereafter without escalation]. The primary endpoint was corticosteroid-free clinical remission with endoscopic improvement [total Mayo score ≤2 with no subscore & gt;1] at both Weeks 26 and 52. Results A total of 121 patients were included: in the “early” group, 25/59 [42.4%] achieved the primary endpoint versus 19/62 [30.6%] in the “late” group [p = 0.18]. There were no significant differences between the two groups in endoscopic improvement [Week 26: “early” 32/59 [54.2%] versus “late” 29/62 [46.8%]; p = 0.412; Week 52: 27/59 [45.8%] versus 25/62 [40.3%]; p = 0.546] or in histological remission [Robarts Histopathology Index & lt;3 without neutrophils in the epithelium and lamina propria] [Week 26: 24/59 [40.7%] versus 21/62 [33.9%]; p = 0.439; Week 52: 22/59 [37.3%] versus 22/62 [35.5%]; p = 0.837] . Conclusions No significant differences in clinical, endoscopic, and histological outcomes were observed between “early” and “late” disease.
Type of Medium:
Online Resource
ISSN:
1873-9946
,
1876-4479
DOI:
10.1093/ecco-jcc/jjad179
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2024
detail.hit.zdb_id:
2390120-2
detail.hit.zdb_id:
2389631-0
